Novavax, Inc. (NASDAQ:NVAX) has a beta value of 1.41 and has seen 4,550,924 shares traded in the recent trading session. The company, currently valued at $5.17 Billion, closed the recent trade at $87.92 per share which meant it gained $10.6 on the day or 13.71% during that session. The NVAX stock price is -0.77% off its 52-week high price of $88.6 and 95.97% above the 52-week low of $3.54. If we look at the company’s 10-day average daily trading volume, we find that it stood at 10.23 Million shares traded. The 3-month trading volume is 9.35 Million shares.
The consensus among analysts is that Novavax, Inc. (NVAX) is a Buy stock at the moment, with a recommendation rating of 2.2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.24.
Novavax, Inc. (NASDAQ:NVAX) trade information
Wall Street analysts have a consensus price target for the stock at $71.8, which means that the shares’ value could jump -18.33% from current levels. The projected low price target is $46 while the price target rests at a high of $101. In that case, then, we find that the current price level is +14.88% off the targeted high while a plunge would see the stock lose -47.68% from current levels.
Novavax, Inc. (NVAX) estimates and forecasts
Figures show that Novavax, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +1834.75% over the past 6 months, with this year growth rate of -89.66%, compared to 9.2% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 85.8% and 86.5% for the next quarter. Revenue growth from the last financial year stood is estimated to be +744%.
5 analysts offering their estimates for the company have set an average revenue estimate of $30.48 Million for the current quarter. 5 have an estimated revenue figure of $47.84 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $3.06 Million for this quarter, and analysts expect sales will grow by 896.1% for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +5.6% over the past 5 years. Earnings growth for 2020 is a modest +44.9% while over the next 5 years, the company’s earnings are expected to increase by 0%.